- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
Eli Lilly's Cialis faces faster-acting competition
April 30, 2012
IBJ Staff and Bloomberg NewsA Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Eli Lilly and
Co.'s Cialis or Pfizer Inc.’s Viagra, has received U.S. regulatory approval.
MorePoison pills remain as Lilly shareholder vote falls short
April 16, 2012
J.K. WallThe proposal garnered support from the owners of 62 percent of Eli Lilly's outstanding shares. To pass, the proposal needed
approval from the owners of 80 percent of Lilly’s shares.
MoreEndocyte could get $1B from Merck development deal
April 16, 2012
Associated PressEndocyte Inc. stock more than doubled in premarket trading after the company entered into an agreement to develop its ovarian
cancer treatment with pharmaceutical giant Merck & Co.
MoreNew Lilly drug has small sales potential
April 9, 2012
J.K. WallEli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker
less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.
MoreExpress Scripts-Medco deal approved by U.S. regulators
April 2, 2012
Bloomberg NewsExpress Scripts Inc.’s $29.1 billion bid for rival drug benefit manager Medco Health Solutions Inc. won unconditional
approval from U.S. antitrust regulators, clearing the way to create the biggest manager of prescription-drug benefits for
corporate and government clients.
MoreLilly receives Europe's OK for new Byetta use
March 23, 2012
IBJ Staff and Associated Press, Associated PressEuropean regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin
Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
MoreLilly to focus on cancer, diabetes in China, CEO says
March 20, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years,
focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.
MoreExpress Scripts’ Medco deal may be delayed by potential suit
March 19, 2012
IBJ Staff and Bloomberg NewsExpress Scripts Inc.’s bid to acquire Medco Health Solutions Inc. and create the largest U.S. pharmacy-benefits manager
may be delayed by a lawsuit being considered by five states.
MoreEndocyte pulls trigger on European drug submission
March 13, 2012
J.K. WallEndocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after
the European Commission granted it orphan drug status.
MoreFTC asks critics of Express Scripts-Medco deal for ideas
March 10, 2012
Bloomberg NewsTwo pharmacy groups opposing Express Scripts Inc.’s proposed acquisition of Medco Health Solutions Inc. said they were
asked by the U.S. Federal Trade Commission to suggest ways to revise the $29.1 billion deal so it wouldn’t harm competition.
MoreFDA removes hurdle in Endocyte's path to drug approval
March 5, 2012
J.K. WallEndocyte Inc. can start enrolling patients again in a clinical trial of its experimental cancer drug, the company announced
Monday, clearing away a hurdle to getting the drug approved in Europe.
MoreNew drugmaker code deprives docs of football, lunch for 2
March 1, 2012
Bloomberg NewsDoctors can still get free samples of medicines, but not football tickets or lunch for their spouses, under a revised code
of conduct drafted by a global drug industry trade group that counts Eli Lilly as a member.
MoreLilly plans 200 jobs at new $440M Ireland plant
February 27, 2012
IBJ Staff and Bloomberg NewsEli Lilly and Co. plans to invest about $440 million in a new pharmaceutical plant at an existing company site in County Cork
in southern Ireland. The facility in Kinsale will require as many as 200 skilled employees when fully operational.
MoreDrugmakers singing same song: 2012 will be tough
February 2, 2012
Associated PressFor drugmakers, the golden era of the 1990s and early part of the last decade, when they seemed to effortlessly churn out
new multibillion-dollar pills for the masses along with double-digit quarterly profit increases, is not even in the rearview
mirror any more.
MoreLilly eying deal with Turkish drug company
January 31, 2012
Bloomberg NewsEli Lilly and Co. is among about a half-dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in
a deal that may value the Turkish drugmaker at $1 billion, sources say.
MoreLilly's ex-partner wins FDA approval for diabetes drug
January 29, 2012
Bloomberg NewsAmylin Pharmaceuticals Inc. and Alkermes Plc have gained U.S. clearance for Bydureon, a once-weekly diabetes shot. Eli Lilly
and Co. co-developed the drug, but ended its partnership with Amylin last year.
MoreIndiana Senate panel backs limits on abortion pill
January 25, 2012
Associated PressThe Senate health committee voted 5-4 in support of the bill that requires that a doctor examine a woman in person before
giving her RU-486, provide written information about the physical risks of abortion and to schedule a follow-up ultrasound.
MoreDeal with Walgreen perplexes Arcadia's investors
January 21, 2012
J.K. WallSomething doesn’t add up about Arcadia Resources Inc.’s agreement to sell its pharmacy business for a low price
of $2 million, according to many of the Indianapolis company’s investors.
MoreLechleiter bets history will repeat for Lilly
January 16, 2012
J.K. WallEli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff
of such spending has dropped off 70 percent in the last decade.
MoreDrugmaker plans 234 Terre Haute jobs by 2016
January 10, 2012
IBJ Staff and Associated PressA California-based pharmaceutical company says it expects to hire 234 people by 2016 at a new operation on the site of a former
Pfizer Inc. drug plant near Terre Haute.
MorePressure rises as Lilly tries squeeze play
January 9, 2012
J.K. WallIndianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire,
even as the company needs to spend more money on marketing and research to boost sales of new drugs.
MoreBoston lawsuit claims DES-breast cancer link
January 8, 2012
Associated PressFifty-three women from around the country are suing drug companies, including Eli Lilly and Co., who made and promoted DES
for millions of pregnant women from about 1938 to the early 1970s.
MoreLilly's 2012 earnings forecast misses analyst estimates
January 5, 2012
Bloomberg News, Associated PressIndianapolis-based Eli Lilly and Co. provided a 2012 earnings forecast Thursday morning that missed analyst estimates by a
wide margin, sending shares down.
MoreLilly challenging Biogen patent in London lawsuit
January 5, 2012
Bloomberg NewsEli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system
diseases.
MoreLilly losing dominance in diabetes treatment
December 31, 2011
J.K. WallEli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses
on other products that have begun to sap the drugmaker's sales.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
You guys have some "interesting" comments to say the least. I hope you will call in and share those opinions starting June 1. I'm looking forward to having you on the air.
For those who let this information strike a nerve, remember that this is still the America that allows the freedom to achieve dreams and goals. Should you really chastise those who are given a perk on a deal that is supported by the consumer (that is until they don't like the deal anymore due to envy) or should the dream of rewards for working be looked at a little closer? I say lets stick to the deal, go to work,earn our keep, shoot for dreams, change our jobs to have that dream or shut up about others achievements ..............while we are still afforded this liberty of America !
Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.